An investor who bought the rights to a life-saving drug and then hiked the price by more than five-thousand percent says he'll now lower the figure, after a massive backlash.
Martin Shkreli's Turing Pharmaceuticals began charging around 750 euro for Daraprim last month.
The drug treats toxoplasmosis, which can cause complications for AIDS patients.
Mr Schkreli insists he wasn't being greedy.
